KIDS vs. ATRI, SILK, FNA, TMCI, AORT, SIBN, EMBC, IRMD, MDXG, and OFIX
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include Atrion (ATRI), Silk Road Medical (SILK), Paragon 28 (FNA), Treace Medical Concepts (TMCI), Artivion (AORT), SI-BONE (SIBN), Embecta (EMBC), Iradimed (IRMD), MiMedx Group (MDXG), and Orthofix Medical (OFIX). These companies are all part of the "surgical & medical instruments" industry.
Atrion (NASDAQ:ATRI) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
OrthoPediatrics received 177 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 64.56% of users gave OrthoPediatrics an outperform vote while only 55.60% of users gave Atrion an outperform vote.
In the previous week, OrthoPediatrics had 16 more articles in the media than Atrion. MarketBeat recorded 24 mentions for OrthoPediatrics and 8 mentions for Atrion. OrthoPediatrics' average media sentiment score of 1.11 beat Atrion's score of 0.48 indicating that Atrion is being referred to more favorably in the media.
66.2% of Atrion shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 22.8% of Atrion shares are owned by insiders. Comparatively, 31.8% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
OrthoPediatrics has a consensus price target of $45.50, suggesting a potential upside of 46.35%. Given Atrion's higher probable upside, analysts clearly believe OrthoPediatrics is more favorable than Atrion.
Atrion has a net margin of 11.46% compared to Atrion's net margin of -13.58%. OrthoPediatrics' return on equity of 8.07% beat Atrion's return on equity.
Atrion has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Atrion has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
Summary
OrthoPediatrics beats Atrion on 9 of the 17 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
